NCT01539083 - Velcade (Bortezomib) Consolidation After Transplant | Biotech Hunter

Enrollment

256

Participants

Timeline

Start Date

January 13, 2012

Primary Completion Date

December 30, 2015

Study Completion Date

January 9, 2018

Conditions

Multiple Myeloma

Interventions

DRUG

Thalidomide

Thalidomide 100 mg tablet, orally.

DRUG

Bortezomib

Bortezomib 1.3 milligram per square meter (mg/m\^2) solution for injection subcutaneously (SC).

DRUG

Cyclophosphamide

Cyclophosphamide 300 mg/m\^2 orally.

DRUG

Dexamethasone

Dexamethasone 20 mg orally.

DRUG

Prednisolone

Prednisolone 50 mg orally.

Trial Locations (23)

Unknown

Adelaide

Camperdown

Geelong

Greenslopes

Heidelberg

Herston

Malvern

Melbourne

Nedlands

Newcastle

Prahran

Sydney

Westmead

Woodville South

Woolloongabba

Beijing

Guangzhou

Shanghai

Tianjin

Busan

Daegu

Jeollanam-do

Ulsan

All Listed Sponsors

lead

Janssen Scientific Affairs, LLC

INDUSTRY